Evidence Intelligence™
- EvidenceScore™
- 84
- Strong
- ImpactScore™
- 70
- Positive
- ConsistencyScore™
- 80
- consistent
Supporting studies: Based on 5 studies
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Empagliflozin improves heart function in type 2 diabetes patients
Last updated July 6, 2026
Key finding
Empagliflozin resulted in a significant higher decrease in the primary endpoint E/e' ratio by -1.18 (95% CI -1.72/-0.65; P < 0.0001) compared with placebo.
This study evaluated the effects of empagliflozin on diastolic function in patients with type 2 diabetes and elevated end-diastolic pressure, finding significant improvements in various cardiovascular and metabolic parameters.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the effects of empagliflozin on diastolic function in patients with type 2 diabetes and elevated end-diastolic pressure, finding significant improvements in various cardiovascular and metabolic parameters.
Clinical relevance
These findings are clinically significant as they suggest that empagliflozin not only aids in managing blood sugar levels but also improves heart function in patients with type 2 diabetes. This dual benefit could lead to better overall health outcomes and reduced cardiovascular risks in this population.
Keep in mind
The study's sample size may limit generalizability. The duration of the study may not capture long-term effects. Potential confounding factors were not fully controlled.
Published in
Journal Reference
Publication details and source links for this paper.
Jürgen HP, Claus J, Andreas S, et al. Empagliflozin Improves Diastolic Function in Patients with Type 2 Diabetes and Elevated End-Diastolic Pressure. Clinical Research in Cardiology. 2023;112(7):911-922. doi:10.1007/s00392-023-02164-w
Main Effects
Empagliflozin significantly decreased the left ventricular E/e' ratio by -1.18 (P < 0.0001).
Empagliflozin led to a significant decrease in body weight (P < 0.001).
Empagliflozin resulted in a significant decrease in HbA1c (P < 0.001).
Empagliflozin significantly increased hemoglobin levels (P < 0.001).
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Empagliflozin and Body weight, HbA1c, Hematocrit, and 4 more.
This study contributes evidence to
Primary intervention
Empagliflozin
Primary outcomes
- Body weight
- HbA1c
- Hematocrit
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
7
Evidence pairs
7
Relationships
3
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
3
Related topics
7
Evidence pairs
685
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 7 evidence relationships
- Includes primary outcome data
- Linked to 3 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
SGLT2 Inhibitors and Body Weight
Related evidence
Evidence relationship
SGLT2 Inhibitors and HbA1c
Save evidence
Evidence relationship
SGLT2 Inhibitors and Uric Acid Levels
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- EvidenceScore™
- 85
- Strong
- ImpactScore™
- 81
- Positive
- ConsistencyScore™
- 88
- consistent
Supporting studies: Based on 8 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Trackerleft ventricular E/e' ratio
Empagliflozin → left ventricular E/e' ratio
Empagliflozin → left ventricular E/e' ratio
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- Empagliflozin improved the left ventricular E/e' ratio significantly.
- Participants experienced a significant reduction in body weight.
- HbA1c levels decreased significantly with empagliflozin treatment.
Who this applies to
- Adults with type 2 diabetes.
- Patients experiencing elevated end-diastolic pressure.
Keep in Mind
- Results may not apply to populations outside the study demographics.
- Long-term effects of empagliflozin were not assessed in this trial.
- Further studies are needed to confirm these findings in diverse populations.
Between the Lines
- The study's sample size may limit generalizability.
- The duration of the study may not capture long-term effects.
- Potential confounding factors were not fully controlled.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on SGLT2 Inhibitors and HbA1c, SGLT2 Inhibitors and Body Weight.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
SGLT2 Inhibitors → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- 85
- Strong
- ImpactScore™
- 81
- Positive
- ConsistencyScore™
- 88
- consistent
Supporting studies: Based on 8 studies
View evidenceMedications
SGLT2 Inhibitors → Body Weight
Medications
Evidence Intelligence™
- EvidenceScore™
- 84
- Strong
- ImpactScore™
- 70
- Positive
- ConsistencyScore™
- 80
- consistent
Supporting studies: Based on 5 studies
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
HbA1c Evidence Hub
All studies measuring HbA1c
8 studies
outcome_hubMeasures HbA1c as a key outcome.
SGLT2 Inhibitors Evidence Hub
All studies on SGLT2 Inhibitors
8 studies
intervention_hubContributes to SGLT2 Inhibitors evidence base.
Body Weight Evidence Hub
All studies measuring Body Weight
5 studies
outcome_hubMeasures Body Weight as a key outcome.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Empagliflozin and HbA1c
Intervention: EmpagliflozinOutcome: HbA1c
8 results
All studies on Empagliflozin and Body weight
Intervention: EmpagliflozinOutcome: Body weight
5 results
All studies on Empagliflozin
Intervention: Empagliflozin
8 results
All studies measuring HbA1c
Outcome: HbA1c
8 results
All studies measuring Body weight
Outcome: Body weight
5 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does SGLT2 Inhibitors affect body weight?
Strong Evidence
SGLT2 Inhibitors may improve Body Weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Strong | EvidenceScore™ 83.8 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 8 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does SGLT2 Inhibitors improve HbA1c?
Strong Evidence
SGLT2 Inhibitors may improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 85.4 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 19 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does SGLT2 Inhibitors improve uric acid levels?
Moderate Evidence
Current evidence does not show a clear benefit of SGLT2 Inhibitors for Uric Acid Levels.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Evidence caveat: The available evidence reports mixed findings.
Ranked evidence signals
- 1
Uric Acid
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
- Only a small number of supporting studies are available.
- Population details are unavailable.
Does Empagliflozin improve red blood cells?
Emerging Evidence
Empagliflozin appears to improve Red Blood Cells.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Red Blood Cells
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Combination therapy improves liver health in type 2 diabetesDietary interventions improve glycemic control in pre-diabetic patientsEmpagliflozin improves glycemic control in type 2 diabetes patientsEmpagliflozin may reduce kidney disease biomarkers but shows mixed effects on albumin in early diabetesEmpagliflozin reduces HbA1c in youth with type 2 diabetes
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.